Associations of AML MRD levels with posttransplant clinical outcomes
Patients with no detectable FLT3 mutations had the best outcomes after an allogenic hematopoietic cell transplant.
List view / Grid view
Patients with no detectable FLT3 mutations had the best outcomes after an allogenic hematopoietic cell transplant.
A new approach called reverse metabolomics has discovered molecules that may serve as a biomarker or a therapeutic target for IBD.
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
A team has shown that the NapA protein, associated with Lyme disease, attracts inflammatory molecules in the body.
A new microfluidic technology has been developed which can profile histone modifications with as few as 100 cells per assay.
A new study has identified a key molecule involved in Lyme arthritis which presents options for preventative therapies.
14 September 2015 | By Victoria White
The potential new antibiotics are unlike contemporary antibiotics because they contain iridium, a silvery-white transition metal...